Value-based insurance design (VBID), conceived by a multi-disciplinary faculty team at the university of Michigan, works on the premise of aligning patients' out-of-pocket costs with the value of ...

Experts discussed how systemic changes need to be made to help improve preventive care access, which in turn can improve outcomes. Accountable care experts say the future of value in Medicare will ...

Value-based insurance designs frequently lower consumers’ cost sharing to motivate healthy behavior, such as adhering to medication regimens. Few health care purchasers have followed the more ...

Healthcare reform is encouraging a lot of experimentation with health insurance, particularly as payers try to reduce healthcare costs, particularly among patients with chronic conditions. A new study ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In the U.S. patient out-of-pocket costs for prescription drugs are ...

High copayments for medical services can cause patients to underuse essential therapies. Value-based health insurance design attempts to address this problem by explicitly linking cost sharing and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Although the gap between low and high value has been established in many areas, insurance design has yet to adapt, according to a panel at the 20th annual Value-Based Insurance Design (VBID) Summit.

Certain elements of value-based insurance design plans may lead to higher medication adherence, according to a study published in Health Affairs. Researchers analyzed 76 VBID plans and their effect on ...

Forty-nine percent of payers questioned believe that Value-Based Insurance Design is the most effective way to improve the performance of Disease Management (DM) and Wellness programs. This, according ...

Public money should not be used to pay for prescription drugs of little to no medical value. To the extent that value-based insurance design, whereby drugs of lower medical value attract a higher ...